Two-Week Radiotherapy Matches Eight-Week for Prostate Cancer Outcomes

A series of landmark clinical trials, including the HYPO-RT-PC trial, have shown that a condensed two- to two-and-a-half-week course of high-dose, precision radiotherapy is as safe and effective as the traditional eight-week regimen for treating localized prostate cancer. These findings, now supported by a decade of follow-up data, demonstrate comparable disease control rates, survival, and side-effect profiles between the short-course and standard protocols. This breakthrough offers significant benefits for patients by reducing treatment burden and disruption to daily life, while also easing pressure on healthcare systems. The studies confirm that fewer, higher doses over a shorter period provide the same long-term outcomes, fundamentally challenging existing treatment standards and empowering clinicians and patients to confidently opt for the shorter schedule.